PrimeGene (Beijing) Overview
- Year Founded
-
2016
- Status
-
IPO Registration
- Employees
-
88
- Latest Deal Type
-
IPO
- (Announced)
- Investors
-
9
PrimeGene (Beijing) General Information
Description
Developer and provider of localized targeted therapies, designed for the treatment of chronic inflammatory diseases. The company focuses on new drug discovery, R&D and commercialization featuring immune/inflammatory diseases and external use, providing new drugs for skin, ophthalmology, rhinology and respiratory system.
Contact Information
Website
www.primegenx.netCorporate Office
- 3rd Floor, Building B, Chongxin Building
- No. 13 Hangfeng Road, Fengtai District
- Beijing, 100070
- China
Corporate Office
- 3rd Floor, Building B, Chongxin Building
- No. 13 Hangfeng Road, Fengtai District
- Beijing, 100070
- China
PrimeGene (Beijing) Timeline
PrimeGene (Beijing) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. IPO | 21-Jan-2026 | Announced | Generating Revenue | |||
| 7. Later Stage VC (Series B) | 02-Jan-2025 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 16-May-2024 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 25-Dec-2023 | Completed | Clinical Trials - General | |||
| 4. IPO | 07-Dec-2022 | Completed | Clinical Trials - General | |||
| 3. Later Stage VC | 31-Aug-2022 | Completed | Clinical Trials - General | |||
| 2. Secondary Transaction - Private | 20-May-2021 | $3.09M | $23.2M | Completed | Clinical Trials - General | |
| 1. Early Stage VC (Series A) | 20-May-2021 | $23.2M | $23.2M | Completed | Clinical Trials - General |
PrimeGene (Beijing) Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| ordinary | ||||||||
| ordinary | ||||||||
| ordinary | 16,666,666 | $1.24 | $1.24 | 1x | $1.24 | 17.35% | ||
| ordinary | 16,666,666 | $1.24 | $1.24 | 1x | $1.24 | 17.35% |
PrimeGene (Beijing) Patents
PrimeGene (Beijing) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026208967-A1 | Mas-related g-protein coupled receptor member x2 antagonist and use thereof | Pending | 03-Apr-2025 | ||
| WO-2026026866-A1 | Macrocyclic compound as tyk2 inhibitor and pharmaceutical composition thereof | Pending | 02-Aug-2024 | ||
| WO-2025256614-A1 | Inhibitor for promoting collagen expression | Pending | 14-Jun-2024 | ||
| WO-2025256631-A1 | Jak inhibitor for treatment of allergic rhinitis | Pending | 14-Jun-2024 | ||
| WO-2025256637-A1 | Tyrosine kinase inhibitor nasal spray | Pending | 14-Jun-2024 |
PrimeGene (Beijing) Signals
PrimeGene (Beijing) Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Beijing E-town International Industrial Investment Management | Government | Minority | ||
| Capital Science and Technology Development Group | Venture Capital | Minority | ||
| Tech Intelligence Capital | Growth/Expansion | Minority | ||
| Beijing State-owned Capital Operation and Management | Government | Minority | ||
| Sunland Fund | Venture Capital | Minority |
PrimeGene (Beijing) FAQs
-
When was PrimeGene (Beijing) founded?
PrimeGene (Beijing) was founded in 2016.
-
Where is PrimeGene (Beijing) headquartered?
PrimeGene (Beijing) is headquartered in Beijing, China.
-
What is the size of PrimeGene (Beijing)?
PrimeGene (Beijing) has 88 total employees.
-
What industry is PrimeGene (Beijing) in?
PrimeGene (Beijing)’s primary industry is Drug Discovery.
-
Is PrimeGene (Beijing) a private or public company?
PrimeGene (Beijing) is a Private company.
-
What is PrimeGene (Beijing)’s current revenue?
The current revenue for PrimeGene (Beijing) is .
-
How much funding has PrimeGene (Beijing) raised over time?
PrimeGene (Beijing) has raised $85.6M.
-
Who are PrimeGene (Beijing)’s investors?
Beijing E-town International Industrial Investment Management, Capital Science and Technology Development Group, Tech Intelligence Capital, Beijing State-owned Capital Operation and Management, and Sunland Fund are 5 of 9 investors who have invested in PrimeGene (Beijing).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process